Abstract 5454
Background
Liver cancer (LC) is presumed to be the sixth most common and newly diagnosed cancer and the fifth leading causing of cancer death around the world in 2018. Hepatocellular carcinoma (HCC) is the most frequent liver cancer and the chronic infection with hepatitis B/C virus is the major risk factor of HCC. Unlike tissue biopsy, liquid biopsy is based on collection of a sample in non-invasive and convenient way at multiple time points over the course of disease. For circulating cell free DNA, it can be used for Next Generation Sequencing (NGS) to detect genetic mutations.
Methods
Whole Blood of patients are collected and plasma was separated. The circulating tumor DNA (ctDNA) is extracted from the plasma samples and quantified using Qubit High Sensitive assay and Agilent D1000 assay. The extracted ctDNA is used for molecular barcoded library construction and captured with probe for next generation sequencing. All samples were then analyzed to identify genetic mutations.
Results
Currently, 20 HCC patients were collected and samples were extracted, sequenced and analyzed. Two thirds of the patients were hepatitis B-viral infected and the one third of the patients were Non-B, Non-C HCC. Most patients were staged 3 others were staged 1 or 2 in HCC. The total ctDNA in 2ml plasma of each patietns were ranged from 2.0 ng to 200ng. As total amount of ctDNA were varied, input ctDNA to construct library was differed ranging from 2ng to 50ng. After molecular tagged libraries were constructed, were pooled and captured with probe for next generation sequencing on Nextseq 500/550 300cycles. Data analysis was performed: TP53 mutations were most frequent and the frequency of mutations are ranged from 3% to 40%.
Conclusions
To fully utilize advantages of the liquid biopsy and circulating tumor DNA, detection of low frequency mutations in the cancer is essential. Detection of low frequency mutation in circulating tumor DNA of hepatocellular carcinoma via optimization of circulating tumor DNA Isolation in plasma samples, optimization of library preparation and target capture condition by using molecular barcoding and customized somatic mutation probe, may improve prognosis, diagnosis, prediction and monitoring of therapeutic response and detection of residual tumor burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract